<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932971</url>
  </required_header>
  <id_info>
    <org_study_id>Hep-Net-HIDIT-II</org_study_id>
    <secondary_id>EudraCT-No.: 2008-005560-13</secondary_id>
    <nct_id>NCT00932971</nct_id>
  </id_info>
  <brief_title>HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis</brief_title>
  <acronym>HIDIT-II</acronym>
  <official_title>A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HepNet Study House, German Liverfoundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Clinical Trial Center GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HepNet Study House, German Liverfoundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind study comparing the efficacy of pegylated interferon-alfa2a plus
      placebo versus pegylated interferon-alfa2a plus tenofovir for the treatment of chronic delta
      hepatitis. 70 Patients will be randomized 1:1 into the two groups. Treatment duration: 96
      weeks. Follow-up: 24 weeks. Long-term-follow-up: until week 358.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2, 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negativation of HDV-RNA at the end of therapy</measure>
    <time_frame>week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negativation of HDV-RNA at week 48 of treatment</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negativation of HDV-RNA 24 weeks after the end of treatment</measure>
    <time_frame>week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of ALT levels at the end of treatment and at the end of follow-up</measure>
    <time_frame>week 96 and week 356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDV-RNA-levels over time</measure>
    <time_frame>up to week 356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of HBV-DNA below 6 IU/ml using the Cobas TaqMan assay at treatment weeks 48 and 96 and 24 weeks after treatment</measure>
    <time_frame>week 48, week 96, week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver histology at end of treatment (Ishak score for inflammation and fibrosis)</measure>
    <time_frame>week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative HBsAg levels over time. Loss of HBsAg and development of anti-HBs antibodies, intrahepatic cccDNA and HBV-DNA levels over time</measure>
    <time_frame>up to week 356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV- and HDV-virus-specific T cell responses during therapy and after 24 weeks of follow up if virological and biochemical efficacy has been shown</measure>
    <time_frame>up week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological long-term outcome</measure>
    <time_frame>1, 2, 3, 4 and 5 years after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical long-term outcome</measure>
    <time_frame>1, 2, 3, 4 and 5 years after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to week 356</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Hepatitis D</condition>
  <arm_group>
    <arm_group_label>PEG-IFN alfa-2a plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-IFN alfa-2a plus Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN alfa-2a, Tenofovir</intervention_name>
    <description>Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally</description>
    <arm_group_label>PEG-IFN alfa-2a plus Tenofovir</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN alfa-2a, placebo</intervention_name>
    <description>Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally</description>
    <arm_group_label>PEG-IFN alfa-2a plus placebo</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Age &gt; 18 years.

          -  Positive HBsAg, for at least the prior 6 months, positive anti-HDV for at least 3
             months and positive for HDV-RNA by PCR within the screening period.

          -  Elevated serum ALT ≥ ULN but ≤ 10X ULN as determined by two abnormal values taken &gt; 1
             month apart during the 12 months before the first dose of study drug with at least one
             of the determinations obtained ≤ 35 days prior to the first dose.

          -  A liver biopsy obtained within the past 12 months demonstrating liver disease
             consistent with chronic hepatitis. Patients with cirrhosis on liver biopsy must also
             have a liver imaging investigation to rule out hepatic carcinoma.

          -  Negative urine or serum pregnancy test documented within the 24 hour period prior to
             the first dose of test drug.

          -  Additionally, all fertile males with partners of childbearing age and females should
             use two reliable forms of effective contraception (combined) throughout the entire
             period of the study (treatment and for 4 months after treatment completion)

          -  Creatinine clearance ≥ 70 mL/min

        Exclusion Criteria:

          -  Patients must not have received antiviral therapy for their chronic hepatitis D within
             the previous 6 months. Patients who are expected to need systemic antiviral therapy
             other than that provided by the study at any time during their participation in the
             study are also excluded.

          -  Positive test at screening for HAV-Ag-IgM, HCV-RNA or HCV-Ag or HIV-Ag.

          -  Serum concentrations of ceruloplasmin or alpha-1-antitrypsin consistent with an
             increased risk of metabolic liver disease.

          -  Evidence of decompensated liver disease (Childs B-C).

          -  History or other evidence of a medical condition associated with chronic liver disease
             (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin
             exposures, thalassemia).

          -  Women with ongoing pregnancy or who are breast feeding.

          -  WBC count of &lt; 3.000 cells/ mm3; neutrophil count &lt; 1.500 cells/mm3or platelet count &lt;
             90.000 cells/mm3.

          -  Evidence of alcohol and/or drug abuse within one year of entry.

          -  Patients are excluded if any history of psychiatric disease, especially depression, or
             of suicidal attempts is evident.

          -  History of immunologically mediated disease.

          -  History or other evidence of decompensated liver disease.

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation.

          -  History of severe cardiac disease

          -  Evidence of an active or suspected cancer or a history of malignancy where there is a
             risk of cancer to recur.

          -  History of having received any systemic anti-neoplastic (including radiation) or
             immunomodulatory treatment (including systemic corticosteroids) ≤ 6 months prior to
             the first dose of study drug or the expectation that such treatment will be needed at
             any time during the study.

          -  History of any organ transplantation with an existing functional graft

          -  History of thyroid disease poorly controlled on prescribed medications. Patients with
             elevated thyroid stimulating hormone concentrations with elevation of antibodies to
             thyroid peroxidase and any clinical manifestations of thyroid disease are excluded.

          -  History or evidence of severe retinopathy or clinically relevant ophthalmological
             disorder.

          -  Inability or unwillingness to provide informed consent or abide by the requirements of
             the study.

          -  History or other evidence of severe illness or any other conditions which would make
             the patient, in the opinion of the investigator, unsuitable for the study.

          -  Patients with a value of alpha-fetoprotein &gt;100 ng/mL are excluded, unless stability
             (less than 10% increase) has been documented over at least the previous 3 months.

          -  History or evidence for any intolerance or hypersensitivity to pegylated
             interferon-alfa-2a, tenofovir or other substances part of the study medication.

          -  Current participation in any other investigational trial and participation in another
             investigational trial within 3 months before the trial begins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Manns, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum, Med. Klinik für Gastroenterologie und Hepatologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Wilhelms-Universität, Med. Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Klinik für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum Innere Medizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät der Universität Heidelberg, Innere Medizin IV</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens University School of Medicine, Hippokration General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Boli Infectioase &quot;Prof. Dr. Matei Bals&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si</name>
      <address>
        <city>Timisoara</city>
        <zip>300312</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-hepatitis.de</url>
  </link>
  <link>
    <url>http://www.hepatitis-delta.org</url>
  </link>
  <reference>
    <citation>Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009 Dec;16(12):883-94. doi: 10.1111/j.1365-2893.2009.01144.x. Epub 2009 Jun 28.</citation>
    <PMID>19566789</PMID>
  </reference>
  <reference>
    <citation>Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27;364(4):322-31. doi: 10.1056/NEJMoa0912696.</citation>
    <PMID>21268724</PMID>
  </reference>
  <reference>
    <citation>Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014 Jul;60(1):87-97. doi: 10.1002/hep.27102.</citation>
    <PMID>24585488</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

